7 research outputs found
Current Performance and On-Going Improvements of the 8.2 m Subaru Telescope
An overview of the current status of the 8.2 m Subaru Telescope constructed
and operated at Mauna Kea, Hawaii, by the National Astronomical Observatory of
Japan is presented. The basic design concept and the verified performance of
the telescope system are described. Also given are the status of the instrument
package offered to the astronomical community, the status of operation, and
some of the future plans. The status of the telescope reported in a number of
SPIE papers as of the summer of 2002 are incorporated with some updates
included as of 2004 February. However, readers are encouraged to check the most
updated status of the telescope through the home page,
http://subarutelescope.org/index.html, and/or the direct contact with the
observatory staff.Comment: 18 pages (17 pages in published version), 29 figures (GIF format),
This is the version before the galley proo
Updated guidance on the management of COVID-19:from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)
BACKGROUND: Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome-coronavirus-2. Consensus suggestions can standardise care, thereby improving outcomes and facilitating future research. METHODS: An International Task Force was composed and agreement regarding courses of action was measured using the Convergence of Opinion on Recommendations and Evidence (CORE) process. 70% agreement was necessary to make a consensus suggestion. RESULTS: The Task Force made consensus suggestions to treat patients with acute COVID-19 pneumonia with remdesivir and dexamethasone but suggested against hydroxychloroquine except in the context of a clinical trial; these are revisions of prior suggestions resulting from the interim publication of several randomised trials. It also suggested that COVID-19 patients with a venous thromboembolic event be treated with therapeutic anticoagulant therapy for 3 months. The Task Force was unable to reach sufficient agreement to yield consensus suggestions for the post-hospital care of COVID-19 survivors. The Task Force fell one vote shy of suggesting routine screening for depression, anxiety and post-traumatic stress disorder. CONCLUSIONS: The Task Force addressed questions related to pharmacotherapy in patients with COVID-19 and the post-hospital care of survivors, yielding several consensus suggestions. Management options for which there is insufficient agreement to formulate a suggestion represent research priorities.status: Published onlin
Recommended from our members
DNA Advanced Glycation End Products (DNA-AGEs) Are Elevated in Urine and Tissue in an Animal Model of Type 2 Diabetes.
More precise identification and treatment monitoring of prediabetic/diabetic individuals will require additional biomarkers to complement existing diagnostic tests. Candidates include hyperglycemia-induced adducts such as advanced glycation end products (AGEs) of proteins, lipids, and DNA. The potential for DNA-AGEs as diabetic biomarkers was examined in a longitudinal study using the Leprdb/db animal model of metabolic syndrome. The DNA-AGE, N2-(1-carboxyethyl)-2'-deoxyguanosine (CEdG) was quantified by mass spectrometry using isotope dilution from the urine and tissue of hyperglycemic and normoglycemic mice. Hyperglycemic mice (fasting plasma glucose, FPG, ≥ 200 mg/dL) displayed a higher median urinary CEdG value (238.4 ± 112.8 pmol/24 h) than normoglycemic mice (16.1 ± 11.8 pmol/24 h). Logistic regression analysis revealed urinary CEdG to be an independent predictor of hyperglycemia. Urinary CEdG was positively correlated with FPG in hyperglycemic animals and with HbA1c for all mice. Average tissue-derived CEdG was also higher in hyperglycemic mice (18.4 CEdG/106 dG) than normoglycemic mice (4.4 CEdG/106 dG). Urinary CEdG was significantly elevated in Leprdb/db mice relative to Leprwt/wt, and tissue CEdG values increased in the order Leprwt/wt < Leprwt/db < Leprdb/db. These data suggest that urinary CEdG measurement may provide a noninvasive quantitative index of glycemic status and augment existing biomarkers for the diagnosis and monitoring of diabetes
DNA Advanced Glycation End Products (DNA-AGEs) Are Elevated in Urine and Tissue in an Animal Model of Type 2 Diabetes
More
precise identification and treatment monitoring of prediabetic/diabetic
individuals will require additional biomarkers to complement existing
diagnostic tests. Candidates include hyperglycemia-induced adducts
such as advanced glycation end products (AGEs) of proteins, lipids,
and DNA. The potential for DNA-AGEs as diabetic biomarkers was examined
in a longitudinal study using the <i>Lepr</i><sup>db/db</sup> animal model of metabolic syndrome. The DNA-AGE, <i>N</i><sup>2</sup>-(1-carboxyethyl)-2′-deoxyguanosine (CEdG) was
quantified by mass spectrometry using isotope dilution from the urine
and tissue of hyperglycemic and normoglycemic mice. Hyperglycemic
mice (fasting plasma glucose, FPG, ≥ 200 mg/dL) displayed a
higher median urinary CEdG value (238.4 ± 112.8 pmol/24 h) than
normoglycemic mice (16.1 ± 11.8 pmol/24 h). Logistic regression
analysis revealed urinary CEdG to be an independent predictor of hyperglycemia.
Urinary CEdG was positively correlated with FPG in hyperglycemic animals
and with HbA1c for all mice. Average tissue-derived CEdG was also
higher in hyperglycemic mice (18.4 CEdG/10<sup>6</sup> dG) than normoglycemic
mice (4.4 CEdG/10<sup>6</sup> dG). Urinary CEdG was significantly
elevated in <i>Lepr</i><sup>db/db</sup> mice relative to <i>Lepr</i><sup>wt/wt</sup>, and tissue CEdG values increased in
the order <i>Lepr</i><sup>wt/wt</sup> < <i>Lepr</i><sup>wt/db</sup> < <i>Lepr</i><sup>db/db</sup>. These
data suggest that urinary CEdG measurement may provide a noninvasive
quantitative index of glycemic status and augment existing biomarkers
for the diagnosis and monitoring of diabetes